

MAF-Test®

How can I optimize
the adjuvant treatment
of my breast cancer?^{1,2}

What is MAF-Test®?

- MAF-Test® is a clinically validated biomarker used to **establish whether you are at higher risk of metastasis** (especially in bone) and to **determine whether adding bisphosphonates early to your treatment may significantly improve your prognosis.**
- The analysis is performed on a **tumor tissue** sample taken during the diagnostic biopsy or surgery, **with no need for additional procedures.**
- This sample is analyzed using a molecular technique called **FISH*** designed to **determine whether or not your tumor shows an increase (amplification) in the number of copies of the MAF gene**, a key gene in the metastatic process.

Why is it important to characterize whether there is MAF amplification in a breast cancer tumor?

80% of breast cancer patients do not have MAF gene amplification, that is, they have a normal number of copies, which is associated with a standard risk of distant recurrence. This risk can nevertheless be reduced by using bisphosphonates together with your adjuvant treatment.

Knowing the MAF status of your tumor allows your doctor to
personalize and optimize the adjuvant treatment of your breast cancer

MAF (-) (not amplified)

MAF (-) (not amplified): indicates a **probable significant benefit** of adjuvant treatment with **bisphosphonates** and a lower risk of breast cancer relapse

MAF (+) (amplified)

MAF (+) (amplified): indicates **potentially unfavorable adjuvant treatment with bisphosphonates** and a higher risk of breast cancer relapse



Who is MAF-Test® indicated for?

1

Patients **newly** diagnosed on breast cancer

2

Patients **with early-stage breast cancer** (stages I-III, without metastasis), regardless of hormone receptor status and other clinicopathological factors.


3

Patients who are **premenopausal and postmenopausal**.

What is the process for the MAF-Test® analysis?

Your Oncologist **prescribes** the MAF-Test® analysis

Your Oncologist receives the **MAF-Test® results** and **personalizes your adjuvant treatment** based on the MAF-Test® results



Your Pathologist uses your **stored tumor sample** to run **MAF-Test®**

* FISH: fluorescence in situ hybridization

References: 1. Pavlovic et al. JNCI (2015); 2. Coleman et al. The Lancet Oncology (2017); 3. Coleman et al. J. Bone Oncol (2018); 4. Paterson et al. J Natl Cancer Inst. Cancer Spectrum (2021); 5. Coleman, RE et al. Ann. Oncol. (2022); 6. Coleman J. Bone Miner. Metab, (2023).